Pharsight

Drugs that contain Ceritinib

1. Zykadia patents expiration

ZYKADIA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7153964 NOVARTIS Pyrimidine compounds
Feb, 2021

(3 years ago)

US8188276 NOVARTIS 2,4-pyrimidinediamine compounds and their uses
Jan, 2023

(1 year, 4 months ago)

US8835430 NOVARTIS 2,4-pyrimidinediamine compounds and their uses
Jan, 2023

(1 year, 4 months ago)

US9416112 NOVARTIS 2,4-pyrimidinediamine compounds and their uses
Jan, 2023

(1 year, 4 months ago)

US9018204 NOVARTIS 2,4-pyrimidinediamine compounds and their uses
Jan, 2023

(1 year, 4 months ago)

US7893074 NOVARTIS 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
Apr, 2026

(1 year, 10 months from now)

US8399450 NOVARTIS Compounds and compositions as protein kinase inhibitors
Nov, 2027

(3 years from now)

US7964592 NOVARTIS 2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
Apr, 2028

(3 years from now)

US8039479 NOVARTIS Compounds and compositions as protein kinase inhibitors
Jun, 2030

(6 years from now)

US8039474 NOVARTIS 2,3,4,9-tetrahydro-1H-carbazole derivatives as CRTH2 receptor antagonists
Jun, 2030

(6 years from now)

US9309229 NOVARTIS Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine
Jan, 2032

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8377921 NOVARTIS Compounds and compositions as protein kinase inhibitors
Nov, 2027

(3 years from now)

US8703787 NOVARTIS Methods of using ALK inhibitors
Feb, 2032

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
ODE*(ODE*) May 26, 2024
New Chemical Entity Exclusivity(NCE) Apr 29, 2019

NCE-1 date: 29 April, 2018

Market Authorisation Date: 18 March, 2019

Treatment: Treatment of a cancer mediated by an anaplastic lymphoma kinase (alk)

Dosage: CAPSULE;ORAL

More Information on Dosage

ZYKADIA family patents

Family Patents